Navigation Links
Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
Date:11/8/2012

GOTHENBURG, Sweden, November 8, 2012 /PRNewswire/ --

Albireo AB (Gothenburg, Sweden; "Albireo"), a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration ("FDA") for the treatment of

  • Progressive Familial Intrahepatic Cholestasis (PFIC)
  • Primary Biliary Cirrhosis (PBC)

Orphan-drug designation is granted by the FDA to novel drugs that seek to treat a rare disease or condition and provides seven years of market exclusivity for the product upon regulatory approval. Albireo has previously received similar orphan drug designation for the same disease areas from the European Commission.

Orphan designation was granted based on an extensive preclinical data package showing that A4250 has a high potency and a minimal systemic exposure. In addition, substantial benefits were shown in an animal model of cholestasis; the predominant feature of PFIC and PBC.

"We are very pleased with the FDA´s recognition of our technology with A4250 as an orphan medicinal product for the treatment of these liver diseases," said Dr. Hans Graffner, Chief Medical officer at Albireo. "This designation is an important milestone in our efforts to provide a treatment for patients with cholestatic liver diseases; a disease entity often leading to severe symptoms, liver transplantation and with reduced survival. A4250 is an inhibitor of the bile acid transport mechanism and will decrease the toxic levels of bile acids in the liver cells. The approvals of the orphan drug designation for A4250 both in Europe and in the US provide evidence of the quality of the A4250 research and give us confidence to move forward with the development of A4250 in these liver diseases."

About A4250
A4250 belongs to a class of inhibitors of the ileal
'/>"/>

SOURCE Albireo AB
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
2. OncoSec Granted New Patent from China
3. Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
4. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
5. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
6. QRxPharma Granted Additional US Patent on MoxDuo®
7. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
8. Broad Patent Protection Granted for iBio Immunomodulator
9. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
10. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
11. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Transparency Market Research has published ... Market (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, ... Volume, Share, Growth, Trends and Forecast 2014 - 2022 ... published by Transparency Market Research " Non-invasive Prenatal Testing ... Trends and Forecast 2014 - 2022 ", the global ...
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics ... over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, announced ... of its ActiPatch 7-day trial device has been ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More ... survey and submitted an assessment.  ...
(Date:8/4/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ) has announced ... Application (Household & Personal Care, Pharmaceutical, Oilfield, Agrochemicals, and ... report to their offering. The ... million in 2014 and is projected to grow at ... The data mentioned in the report is based on ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3
... Compare Genous vs. Drug-Eluting and Bare ... ... in the,randomized TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered R ... April, according to Robbert de Winter, M.D., Ph.D.,principal investigator and director ...
... 16 Protocol Driven Healthcare,Inc. (PDHI) today ... Hallmark Insights to provide fully integrated incentive ... ConXus health improvement platform. ConXus Rewards ... points earned by participants completing activities within ...
Cached Medicine Technology:Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs 2
(Date:8/4/2015)... ... August 04, 2015 , ... Bayco Products, Inc. announces a new industrial-grade ... example, on hard hats that have a flip-up face shield. The sleek contours of ... work without having to remove their headlamp when raising or lowering their face shield ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... United States, Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors effective ... will save lives," Dr. Carmona said. "I strongly believe in the mission of ...
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s 4th Annual ... 3 – 4, 2015, at UC San Diego, will explore innovations that farmers ... access, and manage resources efficiently against the dueling backdrop of a lingering Western ...
(Date:8/4/2015)... ... August 04, 2015 , ... Many men are confused about the safety of ... standing up as a voice of authority for men seeking accurate information about testosterone. ... special experience and expertise in the safe and effective treatment of low testosterone. In ...
(Date:8/4/2015)... ... 04, 2015 , ... They say a picture is worth a thousand words, ... medical art can be essential. StayWell, a health solutions company, announced today it will ... have been used by physicians and other health care providers for more than 40 ...
Breaking Medicine News(10 mins):Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3
... lab and mice studies, compound halts disease without crimping ... A compound derived from hydrangea root, an herb used ... autoimmune disorder in laboratory mice and human cells, new ... promising, the researchers said, is that it slowed progression ...
... www.remudaranch.com ) Reports Many Patients with Eating Disorders Exhibit Weight ... /PRNewswire/ -- Everyone checks their body ... check their body and often in a way that,s unusual. ... , "Sometimes body and weight checking becomes second nature and ...
... CAMBRIDGE, Mass., June 4 Prize4life and the Alzheimer Research Forum ... . ResearchALS.or g ), a web-based resource for ... Gehrig,s disease or motor neuron disease. The site is modeled ... is the first step in Prize4Life,s efforts to build a similar ...
... (Nasdaq: AIRM ), the largest air medical transportation ... Francis Health System and St. John Health System in Tulsa, ... air medical program. This represents the first expansion of Air ... , Effective June 1, 2009, Tulsa Life Flight expanded ...
... LOHAS unites Fortune 500 leaders with emerging entrepreneurs and ... Lifestyles of Health and Sustainability (LOHAS) ... debut of the LOHAS Venture Capital Fair. Through ... facilitates financing of next generation organic and health and ...
... , ... magazine to focus on current on-going research in Asia has been launched by ResearchSEA. , ... (PRWeb UK) June 4, 2009 -- Asia ... been launched by ResearchSEA . Asia is an exciting place for research right now and ...
Cached Medicine News:Health News:Herb May Offer Hope for Autoimmune Diseases 2Health News:Herb May Offer Hope for Autoimmune Diseases 3Health News:Body and Weight Checking May Signify an Eating Disorder 2Health News:Body and Weight Checking May Signify an Eating Disorder 3Health News:Prize4Life and the Alzheimer Research Forum Announce Launch of New Web-Portal for ALS Research 2Health News:Prize4Life and the Alzheimer Research Forum Announce Launch of New Web-Portal for ALS Research 3Health News:Air Methods Expands Community-Based Operations Into Eastern Oklahoma 2Health News:LOHAS Announces Final Program Line-up Including Speakers from Wal-Mart, Coca Cola, MINI, Facebook Causes, Saatchi & SaatchiS, Gaiam and eBay 2Health News:Launch of Asia Research News 2009 2Health News:Launch of Asia Research News 2009 3
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
Medicine Products: